Dual MAPK Inhibition Is an Effective Therapeutic Strategy for a Subset of Class II BRAF Mutant MelanomasMatthew Dankner, April A. N. Rose, Xiu Huang et al.|Clinical Cancer Research|2018Cited by 76
Multi-platform characterization of cutaneous melanoma from patients treated with immune checkpoint inhibitors.Dan Moldoveanu, Ian R. Watson, Mathieu Lajoie et al.|Journal of Clinical Oncology|2018Cited by 0
Dual MAPK inhibition (dMAPKi) as an effective therapeutic strategy for class II BRAF mutant (mt) metastatic melanoma (MM).Matthew Dankner, April A. N. Rose, Mathieu Lajoie et al.|Journal of Clinical Oncology|2018Cited by 0